Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nutex HealthFRA:5LF +3.77%57 Debt-to-EBITDA is 0.68 as of Jun. 2026, which is 30% below its 10-year median of 0.97. GuruFocus rates FRA:5LF with a GF Score™ of 57/100 and a GF Value™ of €70.29 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 482 Healthcare Providers & Services companies, Nutex Health ranks better than 70.75% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nutex Health's Debt-to-EBITDA or its related term are showing as below:
FRA:5LF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -18.91 Med: 0.97 Max: 3.15
Current: 0.9
During the past 7 years, the highest Debt-to-EBITDA Ratio of Nutex Health was 3.15. The lowest was -18.91. And the median was 0.97.
FRA:5LF's Debt-to-EBITDA is ranked better than 70.75% of 482
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs FRA:5LF: 0.90
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nutex Health Debt-to-EBITDA Related Terms
Nutex Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nutex Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5LF vs USPH, AMN, GMRS: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Nutex Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nutex Health Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nutex Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nutex Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Nutex Health (FRA:5LF) has a Debt-to-EBITDA of 0.68 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nutex Health. This is 30% below median its historical median of 0.97. According to the industry distribution chart, Nutex Health ranks #141 out of 482 companies in the Healthcare Providers & Services industry, placing it in the top 29.3%.
Is Nutex Health's Debt-to-EBITDA too high?
Nutex Health's current Debt-to-EBITDA of 0.68 is 30% below median its 10-year median of 0.97. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. Nutex Health's value of 0.68 is 68.9% below this industry median. Based on the distribution chart, Nutex Health ranks #141 out of 482 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Nutex Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nutex Health's Debt-to-EBITDA compare to USPH and AMN?
According to the Healthcare Providers & Services industry distribution chart, Nutex Health ranks #141 out of 482 companies for Debt-to-EBITDA. This puts Nutex Health in the upper half of its industry. The industry median Debt-to-EBITDA is 2.19. Nutex Health's value of 0.68 is 68.9% below this benchmark. While the company's 10-year median is 0.97 vs. the industry median of 2.19, Nutex Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nutex Health's current Debt-to-EBITDA of 0.68 is 68.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nutex Health. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nutex Health's current Debt-to-EBITDA is 0.68, which is 30% below median its own 10-year median of 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nutex Health stock overvalued right now?
Based on GuruFocus' analysis, Nutex Health (FRA:5LF) is currently considered Significantly Overvalued. The stock's GF Value™ is €70.29, compared to a current price of €165.00 — trading 134.7% above its estimated fair value. The current Debt-to-EBITDA is 0.68, which is 30% below median its 10-year median of 0.97 and 68.9% below the Healthcare Providers & Services industry median of 2.19. Nutex Health's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nutex Health (FRA:5LF), the current Debt-to-EBITDA is 0.68 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nutex Health (FRA:5LF) Overvalued in 2026?
Based on GuruFocus' analysis, Nutex Health stock appears to be overvalued.
The current stock price of €165.00 is trading 134.7% above its estimated GF Value™ of €70.29.
GuruFocus considers Nutex Health to be Significantly Overvalued.
Key valuation signals for FRA:5LF:
Debt-to-EBITDA: 0.68 (30% below median its 10-year median of 0.97)
GF Value™: €70.29 vs. price of €165.00 (134.7% above fair value)
Industry Position: 68.9% below the Healthcare Providers & Services median (#141 of 482)
No single metric tells the full story. See the FRA:5LF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
57GF Score
Get the complete analysis for FRA:5LF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5LF has been successfully added to your 
